Mount Sinai researchers reported evidence that wearable health monitoring devices could flag cytokine release syndrome (CRS) earlier in CAR-T-treated multiple myeloma patients. Published in JCI Insight, the study describes a monitoring concept designed to provide an early warning system for CRS, a critical and sometimes fatal complication. The work adds a real-world risk-management angle to CAR-T programs, shifting some attention from only post-event management to earlier identification. By using continuous wearable data, the approach aims to support faster clinical decisions when inflammatory signals start to rise. For biotech developers, CRS remains a major driver of safety burden and inpatient utilization, making detection and management strategies increasingly central to next-generation CAR-T deployment.